RegMed Daily, Mid-Day, 12/12/11, EU continues to rattle markets, so what else is new
The 6 W’s: Who, what, where, when, why and what of it …
Stocks are feeling further … Downside … in Mid-Day Trading … Stocks have moved sharply lower over the course of the trading day on Monday, moving back to the downside after seeing considerable strength last Friday. Renewed concerns about the financial situation in Europe are weighing on the markets …
An interesting quote … “Europe “is moving in the right direction, but it’s going to take longer to fix and probably is not going to happen without a European recession,” said Art Hogan, a strategist at Lazard Capital.
Mid-Day: The NASDAQ is DOWN -47.13 (-1.78%) to 2,599.72. The Dow is Down -229.74 (-1.89%) to 11,954.52.
Mid-Day Movers: Athersys (ATHX) and Pluristem (PSTI)
What’s new in the regenerative medicine/stem cell market:
Geron (GERN) Initiates P2 Trial of GRN1005 in Brain Metastases from Breast Cancer: GERN initiated of GRABM-B (GRN1005 against Brain Metastases – Breast cancer), a P2 clinical trial to evaluate GRN1005 in patients with brain metastases arising from breast cancer. To read the Bottom Line: http://www.scimitarequity.com/blog/2011/12/12/geron-gern-initiates-p2-trial-of-grn1005-in-brain-metastases-from-breast-cancer
Advanced Cell Therapy (ACTC.OB) Settlement Agreements and Preliminary Proxy filed: According to the terms of the agreements, ACT will issue approximately 240.5M shares in total to this group of holders, in exchange for a mutual 2 way release of any current and/or future claims. To read the Bottom Line: http://www.scimitarequity.com/blog/2011/12/12/advanced-cell-therapy-otc-bbactc-settlement-agreements-and-preliminary-proxy-filed
Blood platelets made from adult stem cells: http://in.reuters.com/article/2011/12/11/stemcells-platelets-idINDEE7BA02N20111211 . The Bottom Line: Japanese researchers have reprogrammed adult stem cells to create blood platelet cells. The platelets had the same life span as normal human platelets, researchers reported at a meeting of the American Society of Hematology. The study “has the potential of marching us forward to a day when we might be able to eliminate blood platelet shortages,” said Dr. Charles Abrams of the University of Pennsylvania.
Pancreas study boosts hope for diabetes stem cell treatment: http://www.google.com/hostednews/ukpress/article/ALeqM5juxNDBF-AIvJ1zZDXjnq0Fg6Nj8A?docId=N0384881323572435851A . The Bottom Line: A study of pancreatic agenesis offered insights on how stem cells could be turned into insulin-producing pancreatic beta cells. In 15 out of 27 subjects with pancreatic agenesis, a defective form of the GATA6 gene was found. Researchers hope their study “will help the crucial work to try and make beta cells for patients with type 1 diabetes,” one of the scientists said.
Regenerative Medicine company, BioParadox adds Healthcare and Medical Device Expert, Michael Kleine, to its Board of Directors